Ask the Expert: Working with Regulators to Develop Orphan Drugs

Navigating the Orphan Drug Development Pathway

In this episode of Ask the Expert, Susan J. Schniepp of Regulatory Compliance Associates (RCA), a Nelson Labs company, and Siegfried Schmitt of Parexel discuss regulatory considerations for medium-sized pharmaceutical companies pursuing orphan drug development. The experts explore the unique challenges of developing treatments for rare diseases, including regulatory engagement, clinical development, manufacturing, and commercialization.

Orphan drug designation offers incentives intended to support the development of treatments for small patient populations. These may include grants, tax credits, fee waivers, and additional regulatory support. However, orphan drugs must meet the same rigorous quality and compliance standards as traditional pharmaceutical products, requiring companies to establish effective quality systems and maintain regulatory readiness throughout development.

The experts also highlight operational challenges, including small-batch manufacturing, reliance on contract development and manufacturing organizations (CDMOs), global distribution, and patient recruitment for clinical trials. Companies with limited internal regulatory experience should consider seeking external expertise and maintaining close collaboration with regulatory authorities. Early planning and a flexible development strategy can help companies navigate these challenges while supporting the development of treatments for patients with rare diseases.

Watch the video: Navigating the Orphan Drug Development Pathway

Navigating the Orphan Drug Development Pathway